# A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

> **NCT04088396** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 58 (estimated)

## Conditions studied

- Systemic Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04088396
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-12
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04088396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04088396, "A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04088396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*